Fresenius Medical Care Holdings, Inc., doing business as Fresenius Medical Care North America, owns and operates dialysis facilities, outpatient cardiac and vascular labs, and urgent care centers in North America. It offers health care services for renal and other chronic conditions. The company also provides pharmacy and laboratory services; and manufactures and distributes dialysis equipment, disposable products, and renal pharmaceuticals. In addition, it offers medical care services, such as treatment options programs and patient travel services. Fresenius Medical Care Holdings, Inc. was formerly known as W.R. Grace and Company and changed its name to Fresenius Medical Care Holdings, Inc....
920 Winter Street
Waltham, MA 02451-1457
Founded in 2010
Fresenius Medical Care Holdings, Inc. Presents at FT Global Pharmaceutical and Biotechnology Conference, Nov-15-2016 10:50 AM
Sep 14 16
Fresenius Medical Care Holdings, Inc. Presents at FT Global Pharmaceutical and Biotechnology Conference, Nov-15-2016 10:50 AM. Venue: Grosvenor Square (Entrance on Duke Street), London W1K 6JP, United Kingdom. Speakers: Ronald J. Kuerbitz, Chief Executive Officer.
MemorialCare Health System Enters into Joint Venture Partnership with Fresenius Medical Care North America
Feb 16 16
MemorialCare Health System announced that it has entered into a joint venture partnership with Fresenius Medical Care North America to operate fifteen dialysis clinics in Orange and Los Angeles counties. Thirteen of these clinics are fully operational and two additional clinics are being developed in San Juan Capistrano and Huntington Beach. The partnership will provide comprehensive programs and services, including kidney dialysis treatment, medical services, patient and family support, wellness and prevention, disease management and continuity of health care services to ensure a high quality integrated care experience, while increasing access to community clinics throughout the Southland.
U.S. Judicial Panel on Multidistrict Litigation Issues Order Regarding Fresenius GranuFlo/Naturalyte Dialysate Products Liability Litigation
Dec 8 15
U.S. Judicial Panel on multidistrict litigation issues order regarding Fresenius GranuFlo/NaturaLyte Dialysate products liability litigation. Defendants are Fresenius Medical Care Holdings, Inc. d/b/a Fresenius 1 Medical Care North America; Fresenius USA, Inc.; Fresenius USA Manufacturing, Inc.; and Fresenius USA Marketing, Inc. (collectively Fresenius) oppose the motion. In her motion to vacate, plaintiff principally argues that transfer should not take place unless and until her motion for remand to state court is decided. The company have held that a motion for remand alone generally is an insufficient basis to vacate a conditional transfer order. Indeed, it has 2 rejected similar arguments in support of motions to vacate conditional transfer orders in this litigation. Transfer Order at 1-2, In re Fresenius GranuFlo/NaturaLyte Dialysate Prods. Liab. Litig., MDL No. 2428 (J.P.M.L. Feb. 5, 2015), ECF No. 1023. Plaintiff can present her motion for remand to the transferee judge. See, e.g., In re Ivy, 901 F.2d 7, 9 (2d Cir. 1990); In re Prudential Ins. Co. of Am. Sales Practices Litig., 170 F. Supp. 2d 1346, 1347-48 (J.P.M.L. 2001). Plaintiff also contends that transfer to the District of Massachusetts will be inconvenient because she and many of the witnesses to decedent's dialysis treatment are located in Oklahoma. The Panel has held repeatedly that, while it might inconvenience some parties, transfer of a particular action often is necessary to further the expeditious resolution of the litigation taken as a whole. The transferee judge is in the best position to structure proceedings so as to minimize inconvenience to any individual party. After considering the argument of counsel, find that Jerry involves common questions of fact with the actions previously transferred to MDL No. 2428, and that transfer under 28 U.S.C. Section 1407 will serve the convenience of the parties and witnesses and promote the just and efficient conduct of the litigation. In order centralizing this litigation, held that the District of Massachusetts was an appropriate Section 1407 forum for actions sharing factual questions arising out of allegations that plaintiffs suffered injury or death caused by the use of GranuFlo or NaturaLyte during hemodialysis, which allegedly may cause metabolic alkalosis in patients resulting in low blood pressure, hypokalemia, hypoxemia, hypercapnia, cardiac arrhythmia, or cardiopulmonary arrest. See In re Fresenius GranuFlo/NaturaLyte Dialysate Prods. Liab. Litig., 935 F. Supp. 2d 1362 (J.P.M.L. 2013). Jerry involves similar allegations that plaintiff's decedent suffered metabolic alkalosis, cardiac arrhythmia, and death as a result of the use of GranuFlo and/or NaturaLyte during hemodialysis. This action likewise involves factual questions relating to whether these products were defectively designed or manufactured, whether Fresenius, the manufacturer of these dialysate products, knew or should have known of the alleged propensity of these products to cause injury, and whether it provided adequate instructions and warnings with these products.